Meeting
2023 ASCO Annual Meeting
Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.
Authors
Yongzhao Li
Shijiazhuang People's Hospital, Shijiazhuang, China
Yongzhao Li , Qin Zhang , Qianqian Duan , Tingting Sun , Chuang Qi , Yuan Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9524)
DOI
10.1200/JCO.2023.41.16_suppl.9524
Abstract #
9524
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Improving patient and caregiver understanding of risks and benefits of immunotherapy for melanoma or lung cancer.
First Author: Laura A Petrillo
Poster
2019 ASCO Annual Meeting
Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials.
First Author: Fang Yang
Poster
2024 ASCO Annual Meeting
Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models.
First Author: Vincenzo Quagliariello
Poster
2023 ASCO Quality Care Symposium
Pilot trial of an educational immunotherapy intervention for patients with advanced cancer.
First Author: Laura A Petrillo